| NCT07155668 | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | RECRUITING | PHASE3 | 2025-07-01 | 2026-11 | 2026-07 |
| NCT06812325 | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | RECRUITING | PHASE3 | 2025-02-03 | 2026-12 | 2026-09 |
| NCT06625398 | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-08-27 | 2026-12-15 | 2026-04-01 |
| NCT06625411 | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-08-27 | 2026-11-15 | 2026-03-01 |
| NCT06384547 | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-05-23 | 2026-01 | 2025-05-01 |
| NCT06021054 | An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-14 | 2025-08 | 2024-12-05 |
| NCT06179875 | An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 | COMPLETED | PHASE3 | 2023-02-01 | 2025-06-23 | 2025-04-25 |
| NCT05176639 | A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) | COMPLETED | PHASE3 | 2021-12-03 | 2025-03-27 | 2024-07-15 |